Abstract

BackgroundCardiovascular autonomic dysfunction in cancer survivors is poorly understood.ObjectivesTo better characterize the clinical characteristics and types of autonomic dysfunction in this population.MethodsA retrospective analysis of cancer survivors within an academic cardio-oncology program referred for suspected autonomic dysfunction was performed. Autonomic reflex testing of adrenergic, cardiovagal, and sudomotor function was done. Autonomic impairment was graded on severity based on the Composite Autonomic Severity Score system. Patients with pre-existing autonomic dysfunction prior to their cancer diagnosis were excluded.ResultsOf approximately 282 total patients in the UCLA Cardio-Oncology program, 24 were referred for suspected autonomic dysfunction and met the inclusion criteria. 22 had autonomic impairment on autonomic reflex testing. Eight patients were female, and the mean age at time of autonomic testing was 51.3 years. The average duration from cancer diagnosis to autonomic testing was 10.3 years. The reasons for referral included dizziness, tachycardia, palpitations, and syncope. The majority of patients (75%) had hematologic disorders. The most common chemotherapies administered were vinca alkaloids (54.2%), alkylating agents (66.7%), and anthracyclines (54.2%). Most patients received radiation to the thorax (66.7%) and neck (53.3%). Eleven patients had mild autonomic impairment, 7 had moderate, and 4 had severe autonomic impairment. Dysfunction was commonly present in the sympathetic and parasympathetic branches, but most pronounced in the sympathetic system. The majority of patients were diagnosed with orthostatic hypotension (50%), inappropriate sinus tachycardia (20.8%), and postural orthostatic tachycardia syndrome (12.5%) and had subjective improvement with treatment.ConclusionCardiovascular autonomic dysfunction occurs in cancer survivors, and commonly affects both the sympathetic and parasympathetic systems. Symptom recognition in patients should prompt autonomic testing and treatment where appropriate.

Highlights

  • Cardiovascular autonomic dysfunction in cancer survivors is poorly understood

  • Cardiovascular autonomic dysfunction occurs in cancer survivors, and commonly affects both the sympathetic and parasympathetic systems

  • The 24 patients were referred for suspected cardiovascular autonomic dysfunction based on the presence of typical symptoms or vital sign abnormalities without a definitive alternative cause

Read more

Summary

Introduction

Cardiovascular autonomic dysfunction in cancer survivors is poorly understood. But poorly understood, comorbidity in cancer survivors is cardiovascular autonomic dysfunction [4,5,6]. Autonomic dysfunction is speculated to be an early marker of cardiovascular risk in cancer patients and is associated with an increase allcause mortality [4, 13]. This highlights the potential survival implications of understanding this condition, in addition to managing the debilitating symptoms patients with autonomic dysfunction often face. The subtypes and severity of autonomic dysfunction, and associations with specific treatment agents remain poorly understood

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call